Sinclair IS Pharma PLC (SPH.L)

SPH.L

About

Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems. The Company has presence in five European markets and a marketing partner network across developed and emerging markets. On October 1,... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	1.20
Market Cap (Mil.):	£122.32
Shares Outstanding (Mil.):	434.91
Dividend:	--
Yield (%):	--

Financials

	SPH.L	Industry	Sector
P/E (TTM):	--	35.66	35.83
EPS (TTM):	-0.02	--	--
ROI:	-6.11	19.36	18.72
ROE:	-7.27	20.07	19.54

Latest News about SPH.L

BRIEF-Sinclair IS Pharma signs distribution deals

LONDON, Feb 12 - Sinclair IS Pharma PLC : * Licence and distribution agreement with menarini group in Italy, Spain and

12 Feb 2013

BRIEF-Sinclair IS Pharma's first-half adj loss narrows

LONDON, Feb 12 - Sinclair IS Pharma PLC : * H1 revenues of £23.0 million (H1 12: £23.4 million) * H1 adjusted loss before tax of £0.4 million (H1 12: loss of £0.6 million)

12 Feb 2013

BRIEF-Sinclair IS Pharma sees H1 revenue up 4 pct

LONDON, Jan 10 - Sinclair IS Pharma PLC : * Revenues for the first half expected to be approximately £23.0 million, +4%

10 Jan 2013

BRIEF-Sinclair IS Pharma, Biocodex sign 10-year collaboration and licensing pact

LONDON, Dec 19 - Sinclair IS Pharma PLC : * Sinclair and Biocodex sign 10-year partnership to commercialise portfolio in

19 Dec 2012

» More SPH.L News

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - SINCLAIR IS PHARMA PLC (SPH-LN) Provider: Thomson Reuters Stock Report	$25.00 Buy
Wright Investors Service Comprehensive Report for Sinclair IS Pharma PLC Provider: Wright Reports	$472.00 Buy
Sinclair IS Pharma PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Sinclair Pharma Plc (SPH) - Financial Analysis Review Provider: GlobalData	$125.00 Buy
SINCLAIR PHARMA - STEEP HILL TO CLIMB Provider: Edison Investment Research	$10.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.